Anebulo Receives Positive Feedback From FDA On Path To Phase 3 Trial Of Its Drug For Acute Cannabinoid Intoxication

Anebulo Pharmaceuticals, Inc. ANEB announced positive feedback from the United States Food and Drug Administration following a type B meeting in July. The FDA indicated that a single well-controlled study of ANEB-001 in acute cannabinoid intoxication (ACI) patients presenting to the emergency department combined with a larger THC challenge study in volunteers could potentially provide substantial evidence to support a new drug application.

In addition to receiving the final minutes of the FDA meeting, Anebulo has also completed dosing in an open-label part C extension of its phase 2 clinical trial to evaluate the safety and efficacy of ANEB-001 at higher challenge doses of THC. Twenty healthy adult volunteers (2 cohorts of 10 subjects) participated in part C of the study. Cohort 7 received a single oral dose of 40 mg of THC together with a single oral dose of 10 mg of ANEB-001. Cohort 8 received a single oral dose of 60 mg of THC together with a single oral dose of 20 mg of ANEB-001. In the earlier part B of the study, a single oral dose of 40 mg THC without ANEB-001 was not well tolerated due to overt THC-related effects. However, the use of even higher THC challenge doses was considered acceptable by the IRB provided that all subjects would also receive ANEB-001. Part C of the study was therefore conducted as open-label without a placebo arm.

Subjective and objective assessments performed during the open-label part C of the study were similar to those used in Parts A and B, with the addition of several new outcome measures intended to explore further evidence of clinically meaningful effects. Based on preliminary safety observations, THC challenge doses of 40 mg and 60 mg were well-tolerated when dosed in combination with ANEB-001, and all treatment-related adverse events were mild and transient. Full safety, pharmacokinetic, and pharmacodynamic data from the study, as well as results at higher doses of THC, are expected in Q4 2023.

In addition to the part C extension, Anebulo’s observational pharmacokinetic study in patients reporting to the emergency department with ACI is currently ongoing. Data gathered from these two studies are expected to improve our understanding of the range of THC exposures associated with ACI and the potential for treatment with ANEB-001.

Benzinga Cannabis Capital Conference

The Benzinga Cannabis Capital Conference, the place where deals get done, is returning to Chicago this Sept 27-28 for its 17th edition. Get your tickets today before prices increase and secure a spot at the epicenter of cannabis investment and branding.

Photo: Benzinga edit with photos by Matthias Zomer on Pexels, squarefrog on Pixabay